Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | CCR6 | P51684 | 1/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7489817 | 0.87 | JAK2 (0.52) | SMN1; SMN2KDM4ERAB9ANPC1ALDH1A1 | |
| SCHEMBL858475 | 0.86 | HTT (0.53) | SMN1; SMN2KDM4ERAB9ANPC1MAPT | |
| SCHEMBL13932377 | 0.86 | ALPL (0.41) | KDM4ERAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL14531550 | 0.83 | KDM4E (0.40) | KDM4ERAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL259469 | 0.83 | GAA (0.51) | SMN1; SMN2KDM4EALDH1A1HPGDGAA | |
| SCHEMBL8822098 | 0.80 | PDGFRB (0.38) | SMN1; SMN2KDM4ERAB9AALDH1A1MAPT | |
| SCHEMBL14072015 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2KDM4ERAB9ANPC1ALDH1A1 | |
| SCHEMBL20199406 | 0.79 | KMT2A (0.38) | SMN1; SMN2KDM4ERAB9ANPC1ALDH1A1 | |
| SCHEMBL20477417 | 0.78 | SMN1; SMN2 (0.56) | SMN1; SMN2KDM4ERAB9ANPC1ALDH1A1 | |
| SCHEMBL9324010 | 0.77 | TP53 (0.44) | SMN1; SMN2KDM4ERAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108834415-B | Substituted tricyclic 1, 4-benzodiazepine derivatives as allosteric modulators of group II metabotropic glutamate receptors | 多曼治疗学公司 | 2021-12-24 | — | — | CN | disclosed |
| US-11008323-B2 | Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors | DOMAIN THERAPEUTICS (FR) | 2021-05-18 | — | — | US | disclosed |
| US-20180346468-A1 | SUBSTITUTED TRICYCLIC 1,4-BENZODIAZEPINONE DERIVATIVES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2018-12-06 | — | — | US | disclosed |
| CN-108834415-A | Substituted tricyclic 1, 4-benzodiazepine ketone derivatives as allosteric modulators of group II metabotropic glutamate receptors | 马瓦隆治疗有限公司 | 2018-11-16 | — | — | CN | disclosed |
| EP-3374360-A1 | SUBSTITUTED TRICYCLIC 1,4-BENZODIAZEPINONE DERIVATIVES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | Mavalon Therapeutics Limited (GB) | 2018-09-19 | — | — | EP | disclosed |
| WO-2017081483-A1 | SUBSTITUTED TRICYCLIC 1,4-BENZODIAZEPINONE DERIVATIVES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | MAVALON THERAPEUTICS LIMITED (GB) | 2017-05-18 | — | — | WO | disclosed |
| US-20080255202-A1 | Phenylthioacetic Acid Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-6797824-B2 | UEFUL IN THE DIAGNOSIS AND THERAPY OF AFFECTIVE DISORDERS SUCH AS SCHIZOPHRENIA AND DEPRESSION AS WELL AS CERTAIN MOVEMENT DISORDERS SUCH AS PARKINSONISM | NEUROGEN CORPORATION | 2004-09-28 | — | — | US | disclosed |
| US-20030018025-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands | NEUROGEN CORPORATION, CORPORATION OF THE STATE OF DELAWARE | 2003-01-23 | — | — | US | disclosed |
| US-20020143044-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-10-03 | — | — | US | disclosed |
| US-5646281-A | FOR USE IN THE DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA, DEPRESSION AND PARKINSON*S DISEASE | NEUROGEN CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5633377-A | DIAGNOSIS, THERAPY OF SCHIZOPHRENIA, DEPRESSION, PARKINSON'SDISEASE | NEUROGEN CORPORATION (US) | 1997-05-27 | — | — | US | disclosed |
| EP-0506194-B1 | 4-aryl-thiazole or imidazole derivatives | AKZO NOBEL NV (NL) | 1996-08-21 | — | — | EP | disclosed |
| WO-1996016040-A1 | CERTAIN 4-AMINOMETHYL-2-SUBSTITUTED IMIDAZOLE DERIVATIVES AND 2-AMINOMETHYL-4-SUBSTITUTED IMIDAZOLE DERIVATIVES; NEW CLASSES OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
| US-5462959-A | 4-aryl-imidazole derivatives | AKZO N.V. (NL) | 1995-10-31 | — | — | US | disclosed |
| EP-0365030-B1 | Imidazole compound and process for preparing the same | ISHIHARA SANGYO KAISHA (JP) | 1994-01-26 | — | — | EP | disclosed |
| US-5254575-A | 4-aryl-thiazole derivatives | AKZO N.V. (NL) | 1993-10-19 | — | — | US | disclosed |
| EP-0506194-A1 | 4-aryl-thiazole or imidazole derivatives | Akzo Nobel N.V. (NL) | 1992-09-30 | — | — | EP | disclosed |
| US-5023336-A | Fungicides, biocides | ISHIHARA SANGYO KAISHA LTD. (JP) | 1991-06-11 | — | — | US | disclosed |
| EP-0365030-A1 | Imidazole compound and process for preparing the same | ISHIHARA SANGYO KAISHA, Ltd. (JP) | 1990-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346468-A1 | SUBSTITUTED TRICYCLIC 1,4-BENZODIAZEPINONE DERIVATIVES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM3, GRM1, GRM2 | SMN1; SMN2 3142/4885KDM4E 1300/4885RAB9A 2054/4885 |
| US-20030018025-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands | CHRNA4, GRIA4, OPRM1 | SMN1; SMN2 3134/4885KDM4E 1670/4885RAB9A 1331/4885 |
| US-20020143044-A1 | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands | DRD2, OPRM1, OPRD1 | SMN1; SMN2 3260/4885KDM4E 1563/4885RAB9A 613/4885 |
| US-11008323-B2 | Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group II metabotropic glutamate receptors | GRM3, GRM1, GRM2 | SMN1; SMN2 3142/4885KDM4E 1300/4885RAB9A 2054/4885 |
| US-20080255202-A1 | Phenylthioacetic Acid Derivatives and Use Thereof | PAH, TST, MPST | SMN1; SMN2 4675/4885KDM4E 3732/4885RAB9A 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.